

innate pharma

Q1 2024 Financial Results and Business Update

14 May 2024

EURONEXT : IPH.PA NASDAQ : IPHA

Disclaimer on Forward-Looking Information and Risk Factors

This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed.

This document contains forward-looking statements. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to various risks and uncertainties, which could cause the Company’s actual results or financial condition to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the Autorité des Marchés Financiers (“AMF”), available on the AMF website (www.amf-france.org) or on the Company’s website (www.innate-pharma.com), and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company. Such documents may not be necessarily up to date.

This document contains data pertaining to the Company's potential markets and the industry and environment in which it operates. Some of this data comes from external sources that are recognized in the field or from Company’s estimates based on such sources.

This presentation discusses product candidates that are under clinical development, and which have not yet been approved for marketing by the U.S. Food and Drug Administration or the European Medicines Agency. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied.

The information contained herein has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The Company is under no obligation to keep current the information contained in this presentation and any opinion expressed is subject to change without notice.

The Company shall not bear any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

This document and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares of the Company in any country.

Speakers on Today's Call



Hervé Brailly
PhD

Chief Executive Officer ad interim

Chairman of the Executive Board



Sonia Quaratino
MD, PhD

Chief Medical Officer



Yannis Morel
PhD

Chief Operating Officer




Arvind Sood

President of US Operations

innate pharma


Scientific innovation drives our strategy

Our ambition –
leverage our scientific know-how in innate immunity and antibody engineering to develop cancer drugs that improve the lives of patients.




Lacutamab

Phase 2 MF at ASCO, Continue to pursue Fast-to-market strategy



ANKET® & ADC

IPH6501 at ASCO
IPH45 ADC at AACR
Sanofi progress SAR’579 to Phase 2



Monalizumab

Phase 3 trial underway, further Phase 2 data at ASCO

innate pharma

Innate's approach: harnessing innate immunity in cancer

Choosing the right targets to leverage the body's immune response

01

Engage NK cells towards tumor

Lacutamab (KIR3DL2)

ANKET® Antibody-based NK cell Engager Therapeutics

IPH6501 (CD20-IL2v)
SAR'579, IPH6101 (CD123)
SAR'514, IPH6401 (BCMA)
IPH62 (B7H3)
IPH67

02


Unleash NK cells

Monalizumab (NKG2A)

03

Reverse suppression

IPH5201 (CD39)
IPH5301 (CD73)



Demaria et al., Nature 2018

Modified from Vivier et al., Nature February 2024

innate pharma

Our robust pipeline of proprietary & partnered assets

		Program	Target	Indication	Pre-Clinical	Phase 1	Phase 2	Phase 3	Comments
PROPRIETARY	Monoclonal antibodies	**Lacutamab**	KIR3DL2	Sezary syndrome / MF	Phase 2 TELLOMAK (FDA FAST TRACK/EMA PRIME DESIGNATION)				MF data ASCO 2024
				PTCL	Phase 2 KILT				IST with LYSA
		IPH5301	CD73	Solid tumors	Phase 1 CHANCES				IST with IPC
	ANKET	**IPH6501**	CD20	B-NHL	Phase 1/2				
		Others	Undisclosed		Pre-clinical				
	ADC Antibody Drug Conjugate	**IPH45**	Nectin-4		Pre-clinical				IPH45 IND in 2024
		IPH43	MICA/B		Pre-clinical				
		Other	Undisclosed		Pre-clinical				
PARTNERED	Monoclonal antibodies AstraZeneca	**Monalizumab**	NKG2A	Unresectable Stg III NSCLC	Phase 3 PACIFIC-9				Data readout > 2025
				Neoadjuvant NSCLC	Phase 2 NeoCOAST-2				Data readout > 2025
		IPH5201	CD39	Neoadjuvant NSCLC	Phase 2 MATISSE				
	ANKET sanofi	**SAR'579 / IPH6101**	CD123	R/R AML, B-ALL, HR-MDS	Phase 1/2				
		SAR'514 / IPH6401	BCMA	R/R MM, LCA	Phase 1/2				
		IPH62	B7-H3		Research				
		IPH67	Undisclosed	Solid tumors	Research				
		1 options	Undisclosed		Research				
	ADC Takeda	**Other**	Undisclosed	Celiac disease	Research				

ADC: antibody drug conjugate; GemOx: gemcitabine and oxaliplatin; PTCL: Peripheral T Cell Lymphoma; NSCLC: Non-small cell lung cancer; AML: Acute Myeloid Leukemia; B-ALL: B-cell Acute Lymphoblastic Leukemia; HR-MDS: High Risk-myelodysplasia; MM: Multiple Myeloma; LCA: Light-chain Amyloidosis; IST: investigator-sponsored study; IND: Investigational new drug

innate pharma

Five abstracts selected for ASCO 2024



Lacutamab
Anti KIR3DL2 mAb

Phase 2 TELLOMAK

Top-line phase 2 results
R/R mycosis fungoides cohorts
Abstract #7082

IPH6501
IL2v-armed Tetra-specific ANKET® targeting CD20

Phase 1/2

Trial-In-Progress
IPH6501 in R/R CD20-expressing Non-Hodgkin Lymphoma
Abstract #TPS7095

Preclinical assessment

of IPH6501, a first-in-class IL2v-armed tetraspecific NK cell engager directed against CD20 for R/R B-NHL, in comparison with a CD20-targeting T cell engager
Abstract #7030

Monalizumab
Anti NKG2A mAb

Phase 2 COAST

Updated Phase 2 results
Durvalumab ± oleclumab or monalizumab in stage III unresectable NSCLC (AstraZeneca)
Abstract #8046

Phase 2 MOZART

Trial-In-Progress
Phase 2 trial of monalizumab with durvalumab + chemo for extensive stage small cell lung cancer
Abstract #TPS8129

Lacutamab | Clinical Trials

A potential new standard of care in the T-cell lymphomas expressing KIR3DL2

Cutaneous T cell lymphoma

Sézary syndrome

80-200 patients
>90% KIR3DL2 expression

Mycosis fungoides (MF)

2,200-4,400 patients
~50% KIR3DL2 expression

TELLOMAK

Phase 2 Trial

Sézary syndrome

N=56

Minimum of 2 prior therapies, including mogamulizumab

Mycosis fungoides

N~100

Cohort 2	Cohort 3	Cohort 4 All comers
KIR3DL2 +	KIR3DL2 -	KIR3DL2 +/-

At least 2 prior systemic therapies

65th ASH Annual Meeting

2024 ASCO ANNUAL MEETING

- Sézary syndrome Phase 2 Final data ASH 2023
- Mycosis fungoides Phase 2 Top-line results ASCO 2024

Peripheral T cell lymphoma

~18,000 patients
~50% KIR3DL2 expression

KILT


Phase 2 Trial

Combination with GEMOX chemotherapy (gemcitabine in combination with oxaliplatin) versus GEMOX alone

- Data 2025

IPH6501, a novel CD20-targeting tetraspecific natural killer cell engager issued from ANKET® platform, has started clinical study in B-cell malignancies

IPH6501, the first proprietary tetraspecific ANKET®



Phase 1/2 first-in-human, multicenter, in Patients With Relapsed and/or Refractory Non-Hodgkin Lymphoma
NCT06088654

First patient dosed in March 2024

IPH6501
IL2v-armed Tetra-specific ANKET® targeting CD20

- ❖ **Innovative MOA** ➔ Triggers NK cells for self-expansion (IL2v) and cancer elimination
- ❖ **Differentiate vs allogeneic NK cells** ➔ Drive proliferation of own patient NK cells (no lymphodepletion required)
- ❖ **Overcome resistance (CD16 loss)** ➔ Ensure constant activation of intra-tumoral NK cells through NKp46
- ❖ **Bystander tumor cell killing** ➔ Stimulate NK cell functions and eliminate CD20-negative tumor cells

Multiple ANKET® programs targeting hematological malignancies and solid tumors
SAR443579 progress to Phase 2

Growing clinical pipeline

ANKET® Antibody-based NK cell Engager Therapeutics

SAR443579 / IPH6101 (CD123)	sanofi	Phase 2
SAR'514 / IPH6401 (BCMA)	sanofi	Phase 1 / 2
IPH6501 (CD20)	innate	Phase 1 / 2
IPH62 (B7-H3)	sanofi	Research
IPH67 (Undisclosed, solid tumor)	sanofi	Research
Option	sanofi	Research
Multiple Targets	innate	Research

SAR443579 progress to Ph2

- Clinical **PoC** established in **Phase 1/2** in R/R AML with complete and durable responses in **monotherapy**
- **Fast Track Designation** for the treatment of acute myeloid leukemia

Proprietary IPH6501 in Phase 1/2 in B-NHL : TiP at ASCO 2024

Preclinical poster at ASCO 2024


2024 ASCO ANNUAL MEETING

innate pharma

We are leveraging our antibody expertise by developing differentiated ADCs

ADC Research pipeline – Lead asset at pre-IND stage

IPH45 (Nectin-4)	innate	Pre-IND
IPH43 (MICA/B)	innate	Research
Target (Tumor antigen)	innate	Research
Target (Celiac disease)	Takeda	Research




IPH45 is a novel and differentiated Nectin-4 DAR8 exatecan ADC

Progress towards IND in 2024

Binder

Proprietary humanized anti-Nectin-4 Antibody

- High affinity
- Non-overlapping epitope with EV*
- Fc-competent IgG1, with the ability to mediate ADCC and CDC



Linker

Cleavable

- **Hydrophylic** → improved half life, low clearance
- **Stable** → improved safety with low release of free drug
- **Excellent conjugability** → high yield manufacturing process

Payload

Exatecan, a Topoisomerase I inhibitor

- Active in **EV/MMAE-resistant** models
- **Higher Bystander Effect than EV, leading to stronger activity in Nectin-4 low tumors**
- **DAR = 8**
- Improved **therapeutic index expected**


AACR American Association for Cancer Research ANNUAL MEETING 2024 • SAN DIEGO

* EV = Enfortumab Vedotin

IPH45 has potential for improved clinical benefits across multiple tumor types

Stronger preclinical efficacy than EV with higher bystander effect

- Stronger efficacy than EV in **low Nectin-4 PDX** models of UC tumors
- Anti-tumor activity in **MMAE-refractory** models
- Anti-tumor activity in combination with anti-PD1 in **PD-1-resistant model**



Packages IND in 2024

Productivity with high yield GMP process

Better **hydrophilic** profile than EV

Well **tolerated** in toxicology studies

AACR American Association for Cancer Research
ANNUAL MEETING
2024 • SAN DIEGO

Monalizumab development in progress of Phases 2 and 3 trials

Covering early stages of lung cancer

Stages of the disease

NSCLC Stages I - III resectable

NeoCOAST*

30% major pathological response vs. 11% durvalumab.

Data presented: 2022

AACR American Association for Cancer Research

ESMO congress

Trial in Progress

2023 ASCO ANNUAL MEETING

Posted in: Sept 2023

CANCER DISCOVERY

NeoCOAST-2*

PHASE 2

Patients with Stage II to IIIB NSCLC

Monalizumab + durvalumab + chemotherapy

490 patients (multiple arms)

NSCLC Stage III unresectable

COAST*

~ 60% reduction in the risk of disease progression vs. durvalumab.

~ 15 months average duration of progression-free survival.

Data presented: 2021

ESMO congress

Posted in: April 2022

Journal of Clinical Oncology

Update at

2024 ASCO ANNUAL MEETING

PACIFIC-9*

PHASE 3

Patients with Stage III unresectable NSCLC

Monalizumab + durvalumab

999 patients (3 arms)

* Study run by AstraZeneca

Newsflow and upcoming catalysts

Delivering across our strategic objectives

- IPH5301 (CD73) | Phase 1 data

- SAR'579 / IPH6101 ANKET® (CD123) | Phase 2 (Sanofi)
- SAR'514 / IPH6401 ANKET® (BCMA) | Phase 1 (Sanofi)
- IPH65 ANKET® (CD20) | Phase 1 start
- IPH45 ADC (Nectin-4) | IND

- Lacutamab Phase 2 TELLOMAK | Final data MF ASCO
- Lacutamab CTCL | Next steps

- Monalizumab PACIFIC-9 | Phase 3 readout (AZ)
- Monalizumab NeoCOAST-2 | Phase 2 readout (AZ)
- IPH5201 (CD39) MATISSE | Phase 2 readout (AZ)

- SAR'579 / IPH6101 ANKET® (CD123) | Next steps (Sanofi)
- SAR'514 / IPH6401 ANKET® (BCMA) | Next steps (Sanofi)
- IPH62 ANKET® (B7-H3) | Next Steps (Sanofi)
- IPH67 ANKET® (undisclosed) | Next Steps (Sanofi)
- ANKET® option | (Sanofi)
- IPH6501 ANKET® (CD20) | Phase 1 data
- IPH45 ADC (Nectin-4) | Phase 1 start

- Lacutamab Phase 2 PTCL | Data

2024 **>2025**

Key Takeaways

Create value for patients and shareholders

Established expertise in immuno-pharmacology

- **LACUTAMAB TELLOMAK DATA**
  - Top-line results in mycosis fungoides to be shared at ASCO
  - Regulatory strategy
- **EXPAND ANKET® CLINICAL PORTFOLIO** – LEAD IN HEMATOLOGY INDICATIONS
  - First patient dosed in Ph1/2 clinical trial with IPH6501, a proprietary 2nd generation ANKET® in B-cell NHL
  - SAR'579 progressed to Phase 2 by Sanofi
- **PURSUING DIFFERENTIATED ADCS**
  - IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate oral presentation at AACR 2024

Strong cash position to end 2025

€ 113.9m* as of March 31, 2024 (excluding €4m from Sanofi received in April 2024)

*Including short term investments (€21.3m) and non-current financial instruments (€10.1m)



innate pharma

Thank you

www.innate-pharma.com
investors@innate-pharma.fr

EURONEXT : IPH.PA NASDAQ : IPHA